Draft published for transparency. Pending attorney review.

Last updated October 22, 2026

On this page

Kyros Trials SMS Terms

Program name: Study Messages, powered by Kyros Trials

The short version

You only get texts if you agree. Agreeing is never required to take part in a study.

Texts are about your study: visit reminders, scheduling, and messages from your study team.

Message frequency varies, depending on the study schedule. Message and data rates may apply.

Reply STOP to stop at any time. Reply HELP for help.

Texts won't contain details about your health. They contain generic reminders and a link to sign in, not names or health details.

Carriers aren't responsible for delayed or undelivered messages.

1. Program description

Messages are sent on behalf of the research site you are working with. The research site that invited you (the "Research Site") uses Kyros Trials, provided by Bordano Tissue, LLC, doing business as Kyros Trials ("Kyros Trials"), to send text messages to study participants, prospective participants who asked to be contacted, and their legally authorized representatives. Messages may include visit and appointment reminders, scheduling and rescheduling, eConsent and portal sign-in links, and two-way messages with study staff. The program does not send marketing or promotional messages.

2.1 You receive texts only after you give prior express consent, by choosing to receive texts or telling study staff, who record your choice. Messages identify the messaging program and include STOP and HELP instructions.

2.2 Consent is not a condition of taking part in any study, receiving any service.

2.3 The Research Site records the date, time, method and phone number for each consent.

3. Message frequency and cost

Message frequency varies with your study's visit schedule, depending on the study schedule. Message and data rates may apply according to your mobile plan.

4. Opting out (STOP) and help (HELP)

4.1 Reply STOP to any message to stop receiving texts. You can also revoke consent by contacting study staff or emailing privacy@kyrostrials.com.

4.2 Reply HELP for help, or contact your study team using the details in your study materials. Kyros Trials can help route your request at privacy@kyrostrials.com.

4.3 We honor revocation requests as required by applicable law. Opting in again requires your consent.

4.4 Opting out of texts does not withdraw you from a study. To withdraw from a study, contact the study team.

5. Privacy and content of messages

5.1 Texts are not a secure channel. To protect your privacy, texts contain generic reminders and sign-in links, not names, conditions, medications or study drug details.

5.2 Two-way replies you send may contain information you choose to share. Please do not text urgent medical information; in an emergency call 911.

5.3 Mobile information (phone number and opt-in data) is not shared with or sold to third parties or affiliates for marketing or promotional purposes. Text messaging originator opt-in data and consent will not be shared with any third parties, except service providers that deliver messages on our behalf.

5.4 See the Research Site's privacy notice, Kyros Trials's Privacy Policy and Consumer Health Data Privacy Policy.

6. Carrier disclaimer

Carriers are not liable for delayed or undelivered messages. Supported carriers include major US carriers; availability may vary.

7. Message timing

Study teams must follow applicable messaging consent and timing requirements. Contact your study team about scheduling preferences.

8. Changes and contact

We may change these terms; material changes will be sent by text. Questions: your study team using the contact details in your study materials, or Kyros Trials at privacy@kyrostrials.com.

Reader guidance, separate from the document

This section explains how to review text-message choices. It does not amend the policy or supply missing contract terms. Read the published document above and request the current full agreement where the page is a summary. Your organization should confirm that the wording addresses the intended use before relying on it.

Begin with a list of consent, message frequency, charges and STOP or HELP options. Identify who at the site owns each question and what evidence is needed. A general product description cannot answer every contractual or study-specific issue. Keep unanswered questions in the review record rather than treating silence as a favorable term.

Review the workflow and the evidence

The practical responsibility is your communication preferences and appropriate use of text messages. Ask what record would show that the process was followed and who can review it. A demonstration with sample data can clarify the workflow without disclosing participant information. It does not replace your legal or operational assessment.

For electronic research records, inspect the responsible user, dates, status, record linkage and change history. For public website interactions, review the information requested and the stated purpose. These are different contexts; a business-contact form should not be used to submit source data or confidential study documents.

Keep access and communication specific

Use individual accounts and the access appropriate to the person’s role. A shared login prevents a reliable link between an action and its responsible user. When inviting a reviewer, check the study and access period rather than assuming that a broad organization role is necessary.

For a question about this document, contact legal@kyrostrials.com. For privacy rights or handling concerns, contact privacy@kyrostrials.com. For a technical barrier or service problem, contact support@kyrostrials.com. Include business contact details, the page and the question, but do not paste participant names, health information, credentials or signed study documents into ordinary email.

Plan review before sensitive use

Request the current security summary, provider information and relevant agreement status before transferring sensitive records. Public summaries do not establish BAA execution, a particular vendor arrangement, an uptime guarantee or a certification. If a requirement is unresolved, document it and obtain an answer instead of inferring readiness from a feature being visible.

Your site’s procedures should explain who approves the system’s intended use, how staff are trained and how exceptions are handled. Keep the review proportionate to the study and data involved. A software control supports the procedure; it does not replace investigator responsibility or participant-facing obligations.

Retain context when records move

Before importing or exporting study information, identify the original records, signature evidence and audit histories that must remain available. A spreadsheet can carry values and dates without reproducing the source system’s historical events. Keep source exports and reconcile sample records so a later reviewer can understand the transition.

Review the trust hub for related policies and summaries and the switching guide for a sample migration review plan. Contract-specific archive or exit terms need the full agreement. Customer data is not deleted for non-payment, but your organization still needs to plan record retention and access under the applicable research rules.